Feldman E C, Bruyette D S, Nelson R W, Farver T B
Department of Veterinary Reproduction, University of California, Davis 95616.
J Am Vet Med Assoc. 1990 Jul 1;197(1):71-8.
The effect of orally administered ketoconazole on plasma cortisol concentration in dogs with hyperadrenocorticism was evaluated. Every 30 minutes from 0800 hours through 1600 hours and again at 1800 hours, 2000 hours, and 0800 hours the following morning, 15 clinically normal dogs and 49 dogs with hyperadrenocorticism had plasma samples obtained and analyzed for cortisol concentration. The mean (+/- SD) plasma cortisol concentration for the initial 8-hour testing period was highest in 18 dogs with adrenocortical tumor (5.3 +/- 1.6 micrograms/dl), lowest in 15 control dogs (1.3 +/- 0.5 micrograms/dl), and intermediate in 31 dogs with pituitary-dependent hyperadrenocorticism (PDH; 3.4 +/- 1.2 micrograms/dl). Results in each of the 2 groups of dogs with hyperadrenocorticism were significantly (P less than 0.05) different from results in control dogs, but not from each other. The same cortisol secretory experiment was performed, using 8 dogs with hyperadrenocorticism (5 with PDH; 3 with adrenocortical tumor) before and after administration at 0800 hours of 15 mg of ketoconazole/kg of body weight. Significant (P less than 0.05) decrease in the 8-hour mean plasma cortisol concentration (0.9 +/- 0.2 microgram/dl) was observed, with return to baseline plasma cortisol concentration 24 hours later. Twenty dogs with hyperadrenocorticism (11 with PDH, 9 with adrenocortical tumor) were treated with ketoconazole at a dosage of 15 mg/kg given every 12 hours for a half month to 12 months. The disease in 2 dogs with PDH failed to respond to treatment, but 18 dogs had complete resolution of clinical signs of hyperadrenocorticism and significant (P less than 0.05) reduction in plasma cortisol responsiveness to exogenous adrenocorticotropin (ACTH).(ABSTRACT TRUNCATED AT 250 WORDS)
评估了口服酮康唑对患有肾上腺皮质功能亢进症犬血浆皮质醇浓度的影响。从上午8点至下午4点,每隔30分钟,以及在下午6点、晚上8点和次日上午8点,分别采集15只临床正常犬和49只患有肾上腺皮质功能亢进症犬的血浆样本,并分析皮质醇浓度。在最初8小时的测试期内,18只患有肾上腺皮质肿瘤的犬血浆皮质醇浓度平均值(±标准差)最高(5.3±1.6微克/分升),15只对照犬最低(1.3±0.5微克/分升),31只垂体依赖性肾上腺皮质功能亢进症(PDH)犬居中(3.4±1.2微克/分升)。两组患有肾上腺皮质功能亢进症的犬的结果与对照犬的结果均有显著差异(P<0.05),但两组之间无差异。对8只患有肾上腺皮质功能亢进症的犬(5只患有PDH;3只患有肾上腺皮质肿瘤)在上午8点给予15毫克/千克体重的酮康唑前后进行了相同的皮质醇分泌实验。观察到8小时平均血浆皮质醇浓度显著降低(P<0.05)(0.9±0.2微克/分升),24小时后恢复到基线血浆皮质醇浓度。20只患有肾上腺皮质功能亢进症的犬(11只患有PDH,9只患有肾上腺皮质肿瘤)接受酮康唑治疗,剂量为15毫克/千克,每12小时给药一次,持续半个月至12个月。2只患有PDH的犬对治疗无反应,但18只犬肾上腺皮质功能亢进症的临床症状完全缓解,血浆皮质醇对外源性促肾上腺皮质激素(ACTH)的反应性显著降低(P<0.05)。(摘要截断于250字)